EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Medical Treatment of Acromegaly: Navigating the Present, Shaping the Future

Mônica R Gadelha iD, Luiz Eduardo Wildemberg, Nelma Veronica Marques, Leandro Kasuki

Endocrine Reviews · 24.11.2025 · 46 (6) · 838-855

DOI: 10.1210/endrev/bnaf020 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrine Reviews, online erschienen am 11.07.2025. Verfasst von Mônica R Gadelha und 3 weiteren Autor:innen. Beteiligte Einrichtung: Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal do …. Hauptthemen laut MEDLINE: Acromegaly. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 151 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acromegaly is a chronic systemic disease associated with considerable morbidity due to its many complications, which lead to increased mortality rates. Adequate treatment is essential to reduce the development of long-term complications and to restore mortality rates to those of the general population. Three modalities of treatment are currently available (surgery, medical therapy, and radiotherapy). Surgery is considered the first-line treatment and achieves disease cure in approximately 50% of patients in reference centers. Three drug classes are currently available (somatostatin receptor ligands, dopamine agonists, and growth hormone receptor antagonists); however, disease control is not achieved in a considerable proportion of patients (∼40%). Despite substantial advances in medical therapy over the last few decades, the treatment burden is still high, and quality of life is not fully restored in many patients, even when biochemical control is achieved. Therefore, the development of medications with greater efficacy and/or easier and more convenient administration is an unmet need in the treatment of acromegaly. In addition, shifting from the current trial-and-error approach to a more precise treatment strategy guided by biomarkers predictive of the response to different medical therapies will optimize and improve patient outcomes. In this review, current treatments as well as new drugs in different phases of development are detailed, and the role of precision medicine in the treatment of acromegaly is discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcromegalyHumansDopamine AgonistsHuman Growth HormoneReceptors, Somatostatin

Stichwörter der Autor:innen

GH receptor antagonistacromegalynew drugsprecision medicinesomatostatin receptor ligand

Substanzen

Dopamine AgonistsHuman Growth HormoneReceptors, Somatostatin

Autor:innen und Institutionen

  • Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-913, Brazil.
  • Neuroendocrine Unit, Instituto Estadual do Cérebro Paulo Niemeyer, Secretaria Estadual de Saúde, Rio de Janeiro 20230-140, Brazil.
  • Neuropathology and Molecular Genetics Laboratory, Instituto Estadual do Cérebro Paulo Niemeyer, Secretaria Estadual de Saúde, Rio de Janeiro 20231-092, Brazil.

ORCID-Profile: Mônica R Gadelha

Zitieren

APA

Gadelha, M. R., Wildemberg, L. E., Marques, N. V., & Kasuki, L. (2025). Medical Treatment of Acromegaly: Navigating the Present, Shaping the Future. Endocrine Reviews, 46(6), 838-855. https://doi.org/10.1210/endrev/bnaf020

Vancouver

Gadelha MR, Wildemberg LE, Marques NV, Kasuki L. Medical Treatment of Acromegaly: Navigating the Present, Shaping the Future. Endocrine Reviews. 2025;46(6):838-855. doi:10.1210/endrev/bnaf020

BibTeX
@article{Gadelha2025,
  author = {Gadelha, Mônica R and Wildemberg, Luiz Eduardo and Marques, Nelma Veronica and Kasuki, Leandro},
  title = {Medical Treatment of Acromegaly: Navigating the Present, Shaping the Future},
  journal = {Endocrine Reviews},
  year = {2025},
  volume = {46},
  number = {6},
  pages = {838--855},
  doi = {10.1210/endrev/bnaf020}
}
Kostenlos starten →